Skip to content
You can now search across every topic, entity and event.What's new
Pandemics and Biosecurity
9JUN

WHO defers vaccine-sharing pact to 2027

3 min read
09:58UTC

WHA79 deferred the Pandemic Agreement's vaccine-sharing annex to 2027, leaving the treaty's equity core inoperative during an emergency that has no licensed product to share.

ScienceDeveloping
Key takeaway

The treaty's vaccine-sharing core stays unfinished until 2027, just as an outbreak with no licensed product needs it.

The 79th World Health Assembly (WHA79) deferred adoption of the Pandemic Agreement's Pathogen Access and Benefit-Sharing (PABS) annex to WHA80 in May 2027, or to an earlier special session if a text is ready 1. The next negotiating round, the seventh Intergovernmental Working Group session (IGWG7), is set for 6 to 17 July 2026 2. PABS is the part of the treaty meant to guarantee that countries which share virus samples receive fair access to the vaccines made from them. Tedros Adhanom Ghebreyesus said real progress had been made, and member states cited a need for more time 3.

This is the second slip in a month: negotiators had already agreed to extend the PABS talks at the resumed sixth IGWG session on 1 May . The annex has stalled because high-income states resist binding sharing obligations they fear will constrain their own manufacturers, the same fault line that has dogged every benefit-sharing negotiation since the 2007 dispute over Indonesian H5N1 samples.

The timing gives the deferral its edge. The treaty's vaccine-sharing core stays inoperative at the exact moment a novel-species emergency with no licensed countermeasure would have tested it. If a Bundibugyo vaccine reaches trials this year, there is still no binding legal route to push doses to the low-income countries carrying the outbreak; allocation stays at the discretion of manufacturers and the buyers WHO can pay first. The world adopted the treaty in 2024 and, two years on, still cannot do the one thing its equity advocates designed it to do.

Deep Analysis

In plain English

When a new dangerous virus emerges, countries need to share samples of it quickly so that scientists around the world can study it and start making vaccines. The problem is that in past pandemics, like H1N1 in 2009, the countries that shared their virus samples did not get any of the vaccines that were made from those samples. Rich countries bought them all first. PABS (Pathogen Access and Benefit-Sharing) is meant to be the rule that fixes this: countries share samples and in return get guaranteed access to vaccines produced from them. The 79th World Health Assembly, which met in Geneva in May 2026, pushed the decision on PABS to a 2027 meeting because member states cannot agree on how the rules would work in practice. During the current Bundibugyo Ebola outbreak, there is no licensed vaccine for this species at all; the PABS negotiations apply to future outbreaks where a sharing-and-access mechanism could make the difference between equitable and inequitable vaccine distribution.

First Reported In

Update #4 · Ebola triples, response misfires

Konrad-Adenauer-Stiftung Geneva Multilateral Dialogue· 24 May 2026
Read original
Different Perspectives
UK Health Security Agency
UK Health Security Agency
UKHSA said egg consumption remains the strongest signal in its 207-case Salmonella Enteritidis investigation. The genomic cluster and 38% hospitalisation among people with available information make exposure identification a public-health priority.
GLEWS+
GLEWS+
GLEWS+ assessed spillover risk from clade B MERS in Nile Basin camels as high if the clade establishes, while rating evidence for spread in camel populations low confidence. The joint assessment makes whole-genome sequencing the next test of the threat.
WHO Regional Office for Africa
WHO Regional Office for Africa
WHO's Africa office said transmission in DR Congo is outpacing control efforts after laboratory capacity reached 19 sites and treatment capacity exceeded 1,300 beds. The assessment puts access, insecurity, community deaths and late care-seeking ahead of a simple equipment shortage.
People in Guatemala
People in Guatemala
Guatemala's population now carries the region's largest reported measles burden, with 30,371 confirmed cases and 26 deaths. The scale shifts practical attention from the Mexico-centred frame that followed the World Cup's travel consequences.
Pan American Health Organization
Pan American Health Organization
PAHO rated regional measles risk very high after recording 47,459 confirmed cases and 44 deaths through week 28. It names vaccination coverage, accumulated susceptibles and mass gatherings with broad international participation as general risk factors.
Chinese health authorities
Chinese health authorities
China reported three human H9N2 cases to WHO between 10 and 16 July: two four-year-olds recovered, a 44-year-old man remains in intensive care, the first severity signal in a cluster that has produced 173 cases and 2 deaths globally since 2015. The subtype is distinct from the H5N1 series this topic otherwise tracks.